Literature DB >> 11032599

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

H Ozer1, J O Armitage, C L Bennett, J Crawford, G D Demetri, P A Pizzo, C A Schiffer, T J Smith, G Somlo, J C Wade, J L Wade, R J Winn, A J Wozniak, M R Somerfield.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11032599     DOI： 10.1200/JCO.2000.18.20.3558

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  105 in total

Review 1.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  The role of myelopoietic growth factors in managing cancer in the elderly.

Authors:  Lodovico Balducci; Ignazio Carreca
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Colony-stimulating factors for the management of neutropenia in cancer patients.

Authors:  David C Dale
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

5.  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.

Authors:  Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

Review 6.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  A way forward on the medically appropriate use of white cell growth factors.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

8.  The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.

Authors:  Nissim Haim; Katerina Shulman; Hadassah Goldberg; Medy Tsalic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 9.  The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.

Authors:  Der-Cherng Liang
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Authors:  Arti Hurria; Kelly Brogan; Katherine S Panageas; Ann Jakubowski; Marjorie Zauderer; Carol Pearce; Larry Norton; Jane Howard; Clifford Hudis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.